119 related articles for article (PubMed ID: 15253426)
1. Investigation of doxorubicin resistance in MCF-7 breast cancer cells using shot-gun comparative proteomics with proteolytic 18O labeling.
Brown KJ; Fenselau C
J Proteome Res; 2004; 3(3):455-62. PubMed ID: 15253426
[TBL] [Abstract][Full Text] [Related]
2. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line.
Gehrmann ML; Fenselau C; Hathout Y
J Proteome Res; 2004; 3(3):403-9. PubMed ID: 15253420
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the mitochondrial proteome of adriamycin resistant MCF-7 breast cancer cells.
Strong R; Nakanishi T; Ross D; Fenselau C
J Proteome Res; 2006 Sep; 5(9):2389-95. PubMed ID: 16944951
[TBL] [Abstract][Full Text] [Related]
4. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
5. Peptidyl-Lys metalloendopeptidase-catalyzed 18O labeling for comparative proteomics: application to cytokine/lipolysaccharide-treated human retinal pigment epithelium cell line.
Rao KC; Palamalai V; Dunlevy JR; Miyagi M
Mol Cell Proteomics; 2005 Oct; 4(10):1550-7. PubMed ID: 15998935
[TBL] [Abstract][Full Text] [Related]
6. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
7. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
8. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.
Yao L; Zhang Y; Chen K; Hu X; Xu LX
PLoS One; 2011; 6(9):e24684. PubMed ID: 21931812
[TBL] [Abstract][Full Text] [Related]
9. PA-MSHA inhibits the growth of doxorubicin-resistant MCF-7/ADR human breast cancer cells by downregulating Nrf2/p62.
Wei Y; Liu D; Jin X; Gao P; Wang Q; Zhang J; Zhang N
Cancer Med; 2016 Dec; 5(12):3520-3531. PubMed ID: 27758045
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.
Bober P; Alexovic M; Talian I; Tomkova Z; Viscorova Z; Benckova M; Andrasina I; Ciccocioppo R; Petrovic D; Adamek M; Kruzliak P; Sabo J
J Cancer Res Clin Oncol; 2017 Jan; 143(1):35-42. PubMed ID: 27620743
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin Affects Expression of Proteins of Neuronal Pathways in MCF-7 Breast Cancer Cells.
Petrovic M; Simillion C; Kruzliak P; Sabo J; Heller M
Cancer Genomics Proteomics; 2015; 12(6):347-58. PubMed ID: 26543081
[TBL] [Abstract][Full Text] [Related]
12. Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin.
Chekhun VF; Lukyanova NY; Burlaka CA; Bezdenezhnykh NA; Shpyleva SI; Tryndyak VP; Beland FA; Pogribny IP
Int J Oncol; 2013 Nov; 43(5):1481-6. PubMed ID: 23969999
[TBL] [Abstract][Full Text] [Related]
13. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
14. Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Chewchuk S; Guo B; Parissenti AM
PLoS One; 2017; 12(2):e0172244. PubMed ID: 28196134
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of metabolic labeling for comparative proteomics in breast cancer cells.
Gehrmann ML; Hathout Y; Fenselau C
J Proteome Res; 2004; 3(5):1063-8. PubMed ID: 15473696
[TBL] [Abstract][Full Text] [Related]
16. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
18. Peroxiredoxin proteins protect MCF-7 breast cancer cells from doxorubicin-induced toxicity.
McDonald C; Muhlbauer J; Perlmutter G; Taparra K; Phelan SA
Int J Oncol; 2014 Jul; 45(1):219-26. PubMed ID: 24789097
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Tyrosine Kinase-Regulated Proteome in Breast Cancer by Combined use of RNA interference (RNAi) and Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) Quantitative Proteomics.
Stebbing J; Zhang H; Xu Y; Grothey A; Ajuh P; Angelopoulos N; Giamas G
Mol Cell Proteomics; 2015 Sep; 14(9):2479-92. PubMed ID: 26089344
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic 18O-labeling strategies for quantitative proteomics.
Miyagi M; Rao KC
Mass Spectrom Rev; 2007; 26(1):121-36. PubMed ID: 17086517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
